Hansa Biopharma AB
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant pa… Read more
Hansa Biopharma AB (HNSA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.253x
Based on the latest financial reports, Hansa Biopharma AB (HNSA) has a cash flow conversion efficiency ratio of 0.253x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-111.70 Million) by net assets (Skr-441.06 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Hansa Biopharma AB - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how Hansa Biopharma AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Hansa Biopharma AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hansa Biopharma AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Selvita S.A.
WAR:SLV
|
0.069x |
|
Duos Technologies Group Inc
NASDAQ:DUOT
|
-0.064x |
|
Balaji Amines Limited
NSE:BALAMINES
|
0.011x |
|
Archer Limited
PINK:ARHVF
|
0.032x |
|
Angel Oak Mortgage Inc
NYSE:AOMR
|
0.061x |
|
Avita Medical Ltd
NASDAQ:RCEL
|
0.327x |
|
Nabors Energy Transition Corp. II Class A Ordinary Shares
NASDAQ:NETD
|
-0.004x |
|
Xin Hee Co Ltd
SHE:003016
|
0.007x |
Annual Cash Flow Conversion Efficiency for Hansa Biopharma AB (2008–2024)
The table below shows the annual cash flow conversion efficiency of Hansa Biopharma AB from 2008 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr-589.83 Million | Skr-674.88 Million | 1.144x | -74.58% |
| 2023-12-31 | Skr-167.88 Million | Skr-755.65 Million | 4.501x | +639.82% |
| 2022-12-31 | Skr602.91 Million | Skr-502.73 Million | -0.834x | -31.28% |
| 2021-12-31 | Skr757.57 Million | Skr-481.17 Million | -0.635x | -171.79% |
| 2020-12-31 | Skr1.24 Billion | Skr-290.27 Million | -0.234x | +60.71% |
| 2019-12-31 | Skr562.82 Million | Skr-334.77 Million | -0.595x | -150.04% |
| 2018-12-31 | Skr859.88 Million | Skr-204.56 Million | -0.238x | +0.05% |
| 2017-12-31 | Skr630.66 Million | Skr-150.10 Million | -0.238x | +28.60% |
| 2016-12-31 | Skr283.69 Million | Skr-94.56 Million | -0.333x | -21.99% |
| 2015-12-31 | Skr211.53 Million | Skr-57.80 Million | -0.273x | +42.39% |
| 2014-12-31 | Skr49.80 Million | Skr-23.62 Million | -0.474x | -45.75% |
| 2013-12-31 | Skr45.68 Million | Skr-14.87 Million | -0.325x | +0.26% |
| 2012-12-31 | Skr63.24 Million | Skr-20.63 Million | -0.326x | +58.28% |
| 2011-12-31 | Skr34.71 Million | Skr-27.14 Million | -0.782x | -39.01% |
| 2010-12-31 | Skr32.17 Million | Skr-18.09 Million | -0.563x | -1.64% |
| 2009-12-31 | Skr24.92 Million | Skr-13.79 Million | -0.553x | -44.73% |
| 2008-12-31 | Skr40.73 Million | Skr-15.58 Million | -0.382x | -- |